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FAK inhibition alone or in combination with adjuvant
therapies reduces cancer stem cell activity
Simon Timbrell1,2, Hosam Aglan1,2, Angela Cramer3, Phil Foden4, David Weaver5, Jonathan Pachter5, Aoife Kilgallon1, Robert B. Clarke1,
Gillian Farnie2,6✉ and Nigel J. Bundred 1,4✉
Cancer stem-like cells (CSC) contribute to therapy resistance and recurrence. Focal adhesion kinase (FAK) has a role in CSC
regulation. We determined the effect of FAK inhibition on breast CSC activity alone and in combination with adjuvant therapies.
FAK inhibition reduced CSC activity and self-renewal across all molecular subtypes in primary human breast cancer samples.
Combined FAK and paclitaxel reduced self-renewal in triple negative cell lines. An invasive breast cancer cohort confirmed high FAK
expression correlated with increased risk of recurrence and reduced survival. Co-expression of FAK and CSC markers was associated
with the poorest prognosis, identifying a high-risk patient population. Combined FAK and paclitaxel treatment reduced tumour
size, Ki67, ex-vivo mammospheres and ALDH+ expression in two triple negative patient derived Xenograft (PDX) models.
Combined treatment reduced tumour initiation in a limiting dilution re-implantation PDX model. Combined FAK inhibition with
adjuvant therapy has the potential to improve breast cancer survival.
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INTRODUCTION
Breast cancer affects 1 in 8 women and there remains a need to
improve survival, particularly within triple negative invasive breast
cancer. Evidence indicates cancer stem-like cells (CSC), defined by
their ability to self-renew and form a heterogeneous tumour are
responsible for tumour initiation, maintenance, and metastasis1. In
breast cancer CSC have been shown to be more resistant to
radiotherapy2, endocrine3, and chemotherapy4. The ability of
breast CSC to preferentially survive these treatments alongside
their ability to self-renew and initiate recurrence has led to the
search for anti-cancer stem cell agents5.
One potential target is focal adhesion kinase (FAK). FAK is
classically known for its role in integrin related signalling at focal
adhesions and its association with cell adhesion, survival, and
metastasis6. High FAK expression was first associated with an
invasive phenotype in breast cancer over 20 years ago7, and a
meta-analysis across all solid cancers demonstrated that high FAK
expression was associated with reduced survival8. Studies have
also demonstrated that high FAK expression is associated with a
triple negative phenotype and metastasis, with some showing a
correlation with reduced breast cancer survival (Supplementary
Table 1)9–11.
FAK consists of a central catalytic kinase domain, an N-terminal
4.1-erzin-radixin-moesin domain, a carboxy-terminal and a focal
adhesion targeting domain. Each of these structural domains plays
a different role although their full functions are yet to be
elucidated6. The best characterised mechanism of FAK activation
involves integrin receptor clustering upon binding of cells to the
extracellular matrix leading to autophosphorylation at pTyr397.
However, there are other phosphorylation sites outside of this
activation loop which are involved with different aspects of FAKs
role in tumour growth and metastasis6. FAK expression and active
pTyr397 FAK has been shown to regulate CSC activity within
breast cancer12. FAK ablation decreased the number of CSC
identified using cell surface markers CD24+/CD29+/CD61+ or
ALDH+ expression in a MMTV-PyMT mouse model13. Studies
inhibiting FAK, reducing pTyr397, within invasive breast cancer
and Ductal Carcinoma in Situ (DCIS) demonstrate decreased CSC
activity and therapy resistance, which was associated with a
reduction Wnt signalling12,14.
Breast cancer is currently managed by surgery, followed by
multiple adjuvant therapies including radiotherapy, endocrine
therapy, anti-Her2 agents, and chemotherapy. The addition of FAK
inhibition is reported to overcome resistance to endocrine15 and
chemotherapy16, as measured by tumour growth. This study
investigated whether FAK inhibition in combination with appro-
priate standard adjuvant therapy can reduce tumour growth but
more importantly CSC activity/tumour initiation. In addition, we
used an invasive breast cancer cohort to investigate if high
expression of FAK correlated with known CSC markers, ITGα6
and ALDH1.
RESULTS
pTyr397FAK expression is higher in triple negative breast
cancer cell lines and ALDH+ CSC population
We evaluated FAK expression across a range of invasive ductal cell
lines to determine if high FAK or pTyr397FAK expression was
associated with a particular molecular phenotype. pTyr397FAK
expression was highest in the triple negative cell lines; MDA-MB-
231 and SUM159 (Fig. 1a, b). All invasive ductal carcinoma cell
lines expressed higher levels of FAK and pTyr397FAK when
compared to the normal mammary (MCF10a) and pre-invasive
(DCIS.com) cell lines (Fig. 1a, b). To determine if FAK expression
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was higher in CSC population as opposed to bulk tumour cells, we
utilised flow cytometry to isolate ALDH+ expressing cells in MDA-
MB-231s (see an example of ALDH gating in supplementary figure
1g). Western blot analysis demonstrated that ALDH+ cells express
a 2.5-fold increase in pTyr397FAK compared to ALDH− cells
(Fig. 1c, d). We confirmed that ALDH+ population were enriched
for CSC activity showing increased mammosphere forming
efficiency of 1.41 ± 0.06% compared to 0.64 ± 0.08%, p < 0.0001
in ALDH− cells (Fig. 1e). Although pTyr397FAK was elevated in all
invasive breast cancer cell lines, evidence of increased pTyr397FAK
within ALDH+ cells suggest FAK may be a promising target in
triple negative breast cancers, where there are no current targeted
therapies.
FAK inhibition reduces mammosphere formation across all
molecular phenotypes and improves mammosphere reduction
in combination with Lapatinib in HER2+ cell lines
We investigated whether therapy resistant CSC populations could
be reduced with FAK inhibitor, VS4718, and if combination
treatment with adjuvant therapies would be more effective. Using
Fig. 1 pTyr397FAK expression is higher in triple negative cell lines and ALDH+ cells. FAK inhibition in combination with adjuvant
therapies reduces CSC activity. a Representative Western blot demonstrating baseline expression of pTyr397FAK, FAK, and GAPDH in breast
cell lines including invasive carcinoma cell lines reflecting all molecular phenotypes. b Illustrative plot of relative density of pTyr397FAK to FAK,
with relative density of pTyr397FAK to FAK measured and corrected for GAPDH. pTyr397FAK expression in normal ductal cell line MCF10a used
as comparison. One-way ANOVA with post hoc Dunnett’s test (n= 2 for MCF10a and DCIS.com and n= 3 for IDC cell lines). c Representative
Western blot demonstrating pTyr397FAK expression in ALDH+ and ALDH− MDA-MB-231 cells with illustrative plot of relative densities shown
in (d) (n= 3). e ALDH+ cells have increased primary MFE compared to ALDH− expressing cells. Both D&E analysed using unpaired two tailed t-
test. f FAK inhibition with VS4718 0.5 μM reduced primary MFE as a single agent therapy across all cell lines. This was evaluated alongside 1 μM
of Tamoxifen in MCF7, 0.1 μM of Lapatinib in BT474 and SKBr3 cells and 0.1 μM Paclitaxel in MDA-MB-231 and SUM159 cells. Each experiment
had a minimum of five biological repeats and six technical replicates. g FAK inhibition reduced mammosphere self-renewal in SKBr3 and
SUM159 cells when used as monotherapy and in MDA-MB-231 cells when combined with Paclitaxel. All error bars are mean + SEM. Two-way
ANOVA with post hoc Tukey’s test (ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001).
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the mammosphere assay, which measures changes in CSC activity
in vitro, we investigated the effect of FAK inhibition (VS4718)
alone and in combination with standard adjuvant therapies across
a panel of breast cancer cell lines; MCF7 (ER+/PR+/HER2−)
VS4718 0.5 μM± Tamoxifen 1 µm; BT474 (ER+/PR+/HER2+) and
SKBr3 (ER−/PR−/HER2+) VS4718 0.5 μM± 0.1 µM Lapatinib; MDA-
MB-231 and SUM159 (ER−/PR−/HER2−) VS4718 0.5 μM± 0.1 µM
Paclitaxel. FAK inhibition significantly reduced primary mammo-
sphere formation efficiency across all molecular phenotypes
ranging from 16% in MDA-MB-231 cells to 39% in SUM159 cells
(Fig. 1f). When comparing combination treatment to adjuvant
therapy alone (Tamoxifen, Lapatinib, or Paclitaxel) additional
reductions in mammosphere formation were only significant in
HER2+ve cell lines (BT474 and SKBR3).
FAK inhibition reduces self-renewal in SKBr3 (HER2+) and
SUM159 (triple negative) cell lines and in combination with
Paclitaxel in MDA-MB-231 (triple negative) cells
To investigate the effects of treatments on a key CSC character-
istic, self-renewal, primary mammospheres generated during the
treatments described above were disaggregated to single cell
suspensions and re-seeded for secondary mammosphere forma-
tion without further treatment. These experiments are analogous
to in vivo limiting dilution assays to determine if treatment of the
primary tumour has long lived effects to reduce tumour initiation.
FAK inhibition alone (0.5 µM VS4718) significantly reduced
secondary mammosphere formation/self-renewal by 57.94 ±
10.93% and 52.48 ± 15.20% in SKBr3 and SUM159 cell lines,
respectively (Fig. 1g). In the triple negative MDA-MB-231 and
SUM159 cell lines combined treatment of Paclitaxel (0.1 µM) and
VS4718 (0.5 µM) was sufficient to significantly reduce self-renewal
compared to control by 74.37 ± 19.92% and 86.82 ± 15.52%,
respectively (Fig. 1g). Our data demonstrates FAK inhibition alone
reduces CSC activity (primary mammospheres) in all molecular
subtypes, however combination studies specifically show reduc-
tions in self-renewal after Lapatinib and Paclitaxel in Her2+ and
triple negative cells.
FAK inhibitor VS4718 reduces pTyr397FAK and
mammosphere forming efficiency in a dose dependent
manner in triple negative cell lines
We further explored the effects VS4718 in MDA-MB-231 and
SUM159, as there is need for targeted therapy for this aggressive
breast cancer. VS4718 (0.5 µM) led to a reduction in pTyr397FAK
expression in a time (Fig. 2a, b) and dose dependent manner (Fig.
2c, d). A significant reduction in pTyr397FAK was seen in both
MDA-MB-231 and SUM159s (Fig. 2a, e and Supplementary
Fig. 2a–c) at a dose of 0.5 µM and 6 h post-administration. FAK
inhibition resulted in a dose dependent reduction in primary
mammosphere forming efficiency (Fig. 2f and supplementary 2h),
which correlated reduced pTyr397FAK. Levels of pTyr397 kinase
activity correlated directly with CSC activity indicating this was a
good therapeutic target.
FAK SiRNA knockdown reduces total FAK expression,
mammosphere formation, self-renewal, and ALDH+
population in triple negative cell lines
In order to confirm the reduction in CSC activity was via FAK and
not off target we investigated changes in mammospheres and
self-renewal after SiRNA knockdown of FAK (PTK2). FAK knock-
down with two independent SiRNA (#2, #4) was successful and a
combination of both SiRNA led to a significant reduction 94.58 ±
26.89% in FAK protein expression in MDA-MB-231s (Fig. 2g, h).
Double SiRNA knockdown corresponded with a 76.50 ± 10.24%,
p < 0.01 reduction in primary mammosphere formation (Fig. 2i)
and a 63.66 ± 16.27%, p < 0.05 reduction in self-renewal (Fig. 2j).
Similar results were seen in SUM159s (Supplementary Fig. 2d–h).
FAK knockdown reduced ALDH+ expression in MDA-MB-231s
from 1.12 ± 0.03% in scrambled SiRNA controls to 0.20 ± 0.02%,
p < 0.01 (Fig. 2k–m). These data generated by specific FAK siRNA
knockdown confirm the reduction in CSC activity after VS4718
treatment was principally caused by decreased FAK activity
(pTyr397FAK) and not off target effects.
FAK inhibition reduces primary and secondary mammosphere
formation in patient samples across all molecular phenotypes
The use of patient derived primary breast cancer samples allow
our studies to be verified in early breast cancer cells and not cell
lines derived from metastasis, in addition they are more
representative of the response to treatment seen within a
heterogenous breast cancer population. FAK inhibition reduced
primary mammosphere formation in 16 ER+/PR+/HER2− samples
from 0.78 ± 0.10% to 0.40 ± 0.10%, p < 0.01 (Fig. 3a), which did not
improve in combination with Tamoxifen. In four ER−/PR−/HER2+
samples primary mammosphere formation was reduced from
1.51 ± 0.08% to 0.77 ± 0.08%, p < 0.001 after VS4718 inhibition,
and to 0.63 ± 0.08%, p < 0.001 with Lapatinib alone. No additional
combination effect was seen (Fig. 3b). In six ER−/PR−/HER2−
patient samples, 0.5 µM VS4718 and Paclitaxel alone reduced
primary mammosphere formation from 0.72 ± 0.07% to 0.32 ±
0.07%, p < 0.0001 and 0.40 ± 0.08%, p < 0.001, respectively with no
combination effect (Fig. 3c).
FAK inhibition alone (0.5 µM) resulted in a 54.11 ± 14.40%, p <
0.01 reduction in self-renewal (secondary mammosphere forma-
tion) in eight ER+/PR+/HER2− patient samples. Tamoxifen
treatment alone did not significantly reduce self-renewal or
produce an additional combined effect (Fig. 3d). FAK inhibition
alone reduced self-renewal by 22.52 ± 8.1%, p < 0.05 in 4 ER−
patient samples (Fig. 3e). Images representative of primary and
secondary patient derived mammospheres are shown in Fig. 3f, g,
respectively. These data show FAK inhibition reduced self-renewal
across all molecular phenotypes in early invasive breast cancer
primary patient tissue compared to cell line data, where only
Her2+ and triple negative were affected.
High FAK is associated with poor prognosis
We have shown FAK is important in regulating CSCs therefore we
used a retrospective cohort of patients with invasive ductal
carcinoma to determine if FAK expression was associated with
outcome. High expression was defined using Yom et als criteria17
whereby high intensity staining (Fig. 4d) was present in greater
than 20% of epithelial cells. See Fig. 4a–d for the range of FAK
expression, with smooth muscle actin as an internal control for
moderate staining (Fig. 4c). Low FAK was defined as any other
staining intensity excluding High FAK criteria. High FAK was
associated with reduced breast cancer survival (cox-proportional
hazard regression ratio) HR 4.84, p ≤ 0.001, Fig. 4e. High FAK was
associated with increased metastasis HR 3.02, p ≤ 0.001 and
increased breast cancer recurrence HR 2.05, p= 0.005 (Supple-
mentary Fig. 3a, b).
Phosphorylated Tyr397FAK expression was not associated with
outcome in our cohort (Supplementary Fig. 3c, d). We demon-
strated, with prospective breast cancer tissue collection that
pTyr397FAK degraded in a time dependant manner (pre-fixation),
whereas total FAK expression did not degrade (Supplementary
Fig. 3e). Our cohort was retrospectively collected from formalin
fixed paraffin embedded pathology blocks, where the time
between surgery and tissue fixation was not recorded and is
likely to vary between samples. This may account for the lack of
association of pTyr397FAK with outcome.
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High ALDH1 and ITGα6 expression are both associated with
poor clinical outcome
Since FAK regulates CSC activity, we investigated the expression of
two CSC biomarkers; ALDH117 and ITGα618 alone and co-
expressed with high FAK expression. We evaluated ALDH1
expression using a dual immunofluorescent staining protocol
(Fig. 4f) with epithelial cells identified using a CK18 antibody
conjugated to a green fluorophore and ALDH1 antibody
conjugated with a red fluorophore. High epithelial ALDH1
expression (>5%) was associated with increased risk of breast
cancer death HR 6.58, p= 0.003 (Supplementary Fig. 4a) and
recurrence HR 2.21, p= 0.011 (Supplementary Fig. 4b, c). High
expression of ITGα6 was defined using Friedrich et al.’s criteria18
(Fig. 4h–k). High ITGα6 was associated with ER negative disease
and triple negative phenotype (Supplementary Fig. 4d). High
expression of ITGα6 expression was associated with increased
Fig. 2 FAK inhibition and SiRNA knockdown reduces CSC activity in MDA-MB-231 cells. a Representative Western blot demonstrating that
FAK inhibition with VS4718 resulted in a time dependent reduction in pTyr397FAK with relative protein expression shown in (b) but not FAK (n
= 2). c Representative Western blot demonstrating pharmacological FAK inhibition with VS4718 resulted in a dose dependent reduction in
pTyr397FAK with relative protein expression shown in (d) but not (e) FAK (n= 2). f The dose dependent reduction in pTyr397FAK
corresponded with a reduction in primary MFE. g FAK knockdown using SiRNA resulted in a decrease in FAK expression with relative FAK:
GAPDH after SiRNA knockdown shown in (h) relative density plot which correlated with a reduction in (i) primary MFE and (j) mammosphere
self-renewal. One-way ANOVA with post hoc Dunnett’s test. k Representative FACS plots in scrambled controls and (l) SiRNA knockdown. m
Graph demonstrating that FAK knockdown using SiRNA constructs 2 and 4 reduced ALDH+ expression (n= 2). Unpaired two-tailed t-test. (ns
not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001). All experiments were n= 3 unless otherwise stated and error bars represent
mean + SEM.
S. Timbrell et al.
4
npj Breast Cancer (2021)    65 Published in partnership with the Breast Cancer Research Foundation
breast cancer death HR 2.23, p= 0.03 (Supplementary Fig. 4e) and
metastasis HR 2.17, p= 0.008 (Supplementary Fig. 4f).
High co-expression of FAK and CSC markers ALDH1 and ITGα6
is associated with the poorest prognosis
Co-expression of high FAK and ALDH1 was associated with an
increased risk of breast cancer death HR 16.70, p=< 0.001. These
breast cancer deaths occurred within the first 40 months (Fig. 4g).
High FAK and high ITGα6 was associated with an increased risk of
breast cancer death HR 12.83, p=< 0.001, Fig. 4l. This data further
suggests the link between FAK expression and CSC activity and
also identifies a high-risk patient population.
In vivo FAK inhibition reduces tumour growth and Ki67
expression in two triple negative PDX models
To confirm our in vitro data we selected two triple negative
patient derived xenograft (PDX) models RC37 and RC193
(Supplementary Fig. 5b–d). VS4718 50mg/kg given twice daily
via oral gavage led to a 60.24% ± 11.13, p= 0.010 and a 57.58% ±
14.22, p= 0.016 reduction tumour volume in RC37 and RC193
respectively (Fig. 5a, b). VS4718 treatment reduced proliferation
marker Ki67 by 23.7% ± 12.1, p < 0.0001 compared to vehicle
control (Fig. 5c, d). Combined VS4718 and Paclitaxel treatment did
not reduce Ki67 expression further (mean reduction 18.3 ± 12.1%,
p= 0.0022; Fig. 5d). There was a trend to suggest 7.5 mg/kg of
Paclitaxel alone reduced Ki67 with a mean difference of 12.0%
Fig. 3 FAK inhibition reduces primary and secondary sphere formation across all molecular phenotypes in patient samples. a FAK
inhibition with 0.5 μM VS4718 reduces primary mammosphere formation in 16 ER+/PR+/HER2− patient samples. b 0.5 μM VS4718 and 0.1 μM
Lapatinib reduced primary MFE in four ER−/PR−/HER2+ patient samples. c 0.5 μM VS4718 and 0.1 μM Paclitaxel reduced primary MFE in six
ER−/PR−/HER2− patient samples. Each patient had a minimum of six technical replicate values for MFE. d Graph demonstrating that FAK
inhibition reduces mammosphere self-renewal in eight ER+/PR+/HER2− samples. Data in (a–d) analysed using Two-way ANOVA with post
hoc Tukeys test. e Graph demonstrating that FAK inhibition in ER negative patient samples reduces mammosphere self-renewal. Unpaired
two-tailed t-test. (ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001). All error bars represent mean + SEM. Photomicrographs
taken at ×40 magnification of (f) primary patient mammosphere after VS4718 treatment (g) secondary mammosphere in DMSO group with
50 µM scale bars.
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Fig. 4 High FAK and high FAK/ALDH1 or FAK/ITGα6 expression is associated with reduced breast cancer survival. Representative
photomicrographs of FAK staining taken at ×40 magnification with 10 µM scale bars demonstrating; a no staining, b weak staining, c
moderate staining, and (d) high staining. High FAK expression was defined as high intensity staining in greater than 20% of epithelial cells as
per Yom et al. criteria. e Kaplan–Meier demonstrating high FAK was associated with reduced survival, HR 4.84 (2.33–10.04, Cox-proportional
regression p < 0.001). f Representative photomicrograph, with 100 µM scale bar of immunofluorescence staining with epithelial cells isolated
using a CK18 antibody conjugated with a green fluorophore and ALDH1 conjugated to a red fluorophore. Automated analysis of dual staining
was then undertaken using the HALO imaging system with a preview window at ×12 magnification demonstrating how the co-detection
system worked. g Kaplan–Meier demonstrating high co-expression of FAK and ALDH1 (defined as greater than 5% epithelial positivity) is
associated with an increased risk of breast cancer death (n= 162) HR 16.7 (5.21–38.05, Cox-proportional hazard regression p < 0.001).
Representative photomicrographs of ITGα6 staining taken at ×40 magnification with 10 µM scale bar demonstrating; h no staining, i weak
staining, j moderate staining, and (k) high staining. High ITGα6 was defined using Friedrich et als criteria of moderate or high intensity in
greater than 5% of epithelial cells. l Kaplan–Meier demonstrating the association of high FAK and high ITGα6 expression with reduced survival
(n= 230). HR 12.83 (4.43–37.13, Cox-proportional hazard regression p < 0.001).
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p= 0.057. This suggests VS4718 reduces the proliferation of bulk
tumour cells as well as CSC activity.
In vivo FAK inhibition in two triple negative PDX reduces
ex vivo mammosphere formation, ALDH+ CSC population and
tumour initiating capacity
To evaluate if the reduction in growth and proliferation during
FAK inhibitor treatment corresponded with a decreased CSC
activity, we isolated tumour cells from treated PDX tumours and
measured ex vivo mammosphere forming ability (representative
photomicrographs Fig. 6c–e), ALDH+ CSC population (Supple-
mentary Fig. 1a–f) and tumour initiating capacity. In vivo
administration of VS4718 decreased ex vivo mammosphere
formation by 38% in RC37 from 1.79 to 1.12%, p= 0.005.
Combined VS4718 and Paclitaxel resulted in a further reduction
(45%) in ex vivo mammosphere formation to 0.99%, p < 0.001
(Fig. 6a). The second PDX model, RC193, showed similar results.
VS4718 reduced ex vivo mammosphere formation by 61.1% from
1.85 to 0.71%, p < 0.001 and VS4718 alone resulted in a reduction
in mammosphere formation relative to Paclitaxel from 1.65 to
0.72%, p < 0.001 (Fig. 6b). No change in ALDH+ CSC populations
were seen in treated compared to control tumours in the RC37,
but a reduction in ALDH+ CSC population was observed when
comparing Paclitaxel (1.19%) to VS4718-treated PDX (0.24%,
p= 0.033) (Fig. 6f). RC193 had a larger ALDH+ CSC population in
control conditions (1.41%), here FAK inhibition resulted in a
decrease in ALDH+ cells to 0.97%, p < 0.001 (Fig. 6g).
Cells from the treated tumours were also re-implanted into
recipient mice at limiting dilution and tumour initiating capacity
(TIC) calculated using the extreme limiting dilution assay (ELDA).
PDX treated with a combination of VS4718 and Paclitaxel had a
significant reduction in TIC with no tumours forming when 1000
cells were implanted into NSG mice (Fig. 6h). Even when 10,000
cells were implanted only one out of four tumours formed after
60 days compared to four out of four across the remaining groups
Fig. 5 FAK inhibition reduces primary tumour growth and proliferation in triple negative PDX models. a Tumour growth curve
demonstrating that 50mg/kg per oral VS4718 on weekdays as monotherapy and combined weekly Paclitaxel 7.5 mg/kg via intraperitoneal
injection reduces relative tumour growth compared to control mice in RC 37. b Tumour curve demonstrating that combined FAK and
Paclitaxel reduced tumour growth relative to control in RC193. Two-way ANOVA with post hoc Dunnett’s test. c) Photomicrographs of
Ki67 staining with associated 100 µm scale bars. Second column demonstrates the automated scoring system used by the HALO system to
score the number of positive nuclei shown in red. d 0.5 μM VS4718 reduced Ki67 expression in RC37. Two-way ANOVA with post hoc Tukeys
test (ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001). All error bars represent mean + SEM.
S. Timbrell et al.
7
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2021)    65 
Fig. 6 FAK inhibition reduces ex vivo mammosphere formation, ALDH+ expression and tumour initiating capacity. a Graph
demonstrating that FAK inhibition reduced ex vivo MFE when used alone or with Paclitaxel in RC37. b Graph demonstrating that VS4718
reduced MFE relative to control and Paclitaxel treated mice in RC193. Photomicrograph taken at ×40 magnification and 50 µM scale bars of
mammospheres isolated ex vivo from; c RC37 control group, d RC37 VS4718 treated group, and e RC193 control receiving group. f Graph
demonstrating a reduction in ALDH+ expression in VS4718 treated mice as opposed to Paclitaxel treated mice in RC37. g Graph
demonstrating that VS4718 reduced ALDH+ in RC193 relative to control mice. Data in (a, b, f, and g) analysed using Two-way ANOVA with post
hoc Dunnett’s test. h FACS plots demonstrating the identification of epithelial staining of ALDH was identified using PDX model. General cells
were selected, then live cells isolated using 7AAD. Mouse cells were then excluded using H2KD. For the Aldefluor assay the DEAB control was
set at 0.1%. With ALDH+ expression in control mice and VS4718 treated mice in the RC193 model shown in the last two panels. i Limiting
dilution table demonstrating that combined FAK inhibition and Paclitaxel treatment led to a reduction in tumour initiating capacity. Tumours
were defined based on size greater than 100mm3 at Day 60 and ELDA analysis performed using online tool at: http://bioinf.wehi.edu.au/
software/elda. j Combined FAK inhibition and Paclitaxel treatment resulted in a reduction in tumour size in the 100,000 cells per flank
transplantation on Day 48. Data are represented as mean + SEM. (One-way ANOVA analysis with post hoc Dunnett’s test; *p < 0.05).
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(Fig. 6h). TIC frequency in control tumours was one in every 1408
cells, compared with one in every 27,651 within those tumours
harvested from PDX receiving combined VS4718 and Paclitaxel
treatment (p < 0.001, Fig. 6h). It is important to note that one
mouse died in the control group (1000 cells) and if tumours were
to have formed in this mouse, we anticipate that there may have
been a significant reduction in TIC after VS4718 alone.
As well as reducing TIC on serial transplantation, combined
VS4718 and Paclitaxel treatment significantly reduced tumour
growth rate by 52.26% compared to control at day 48 when
100,000 cells were re-implanted, p < 0.05 (Fig. 6i). Thus, combined
FAK inhibition and Paclitaxel treatment reduced TIC and the rate
of subsequent re-growth which would improve long term survival.
DISCUSSION
FAK inhibition, via reduction in pTyr397FAK, reduced CSC activity
and self-renewal across all molecular subtypes in primary human
breast cancer samples. Our studies show that FAK inhibition in
combination with adjuvant therapies, Lapatinib and Paclitaxel,
improved reduction of CSC activity in Her2+ and triple negative
breast cancer cell lines. Importantly, FAK and Paclitaxel combina-
tion studies demonstrate a reduction in the frequency of tumour
initiating cells, alongside ex vivo mammosphere formation and
ALDH+ expression, in a triple negative PDX.
In our retrospective case–control cohort, we demonstrate that
high FAK expression, but not pTyr397FAK, was associated with
reduced breast cancer survival and increased risk of recurrence, in
keeping with a meta-analysis in solid cancers8. Unlike FAK
expression, pTyr397FAK staining demonstrated degradation of
pTyr397FAK, as seen with other phosphorylated proteins19 with
increasing time to fixation. This suggests pTyr397FAK staining may
not be reliable within retrospective cohorts and to validate
pTyr397FAK expression in clinical specimens prospective studies
should formalin fix tissue <1 h after excision20. High CSC marker
expression alone (ALDH1 or ITGα6) was associated with a poor
prognosis in our cohort as previously reported18,21–23. Co-
expression of high FAK expression and high expression of either
CSC marker (ALDH1 or ITGα6) is associated with a particularly poor
prognosis identifying a high-risk patient population, which are
likely to benefit from FAK inhibition.
High FAK expression has previously been shown in anoikis
resistant CSC cell populations within DCIS models14 and FAK
inhibition causes preferential cell death within ALDH+ MDA-MB-
231 and SUM159 CSC populations12. Our study shows ALDH+ cells
were enriched for mammosphere forming cells21 and expressed
greater pTyr397FAK, suggesting FAK inhibition preferentially
targets CSC-like cells. This is in agreement with our in vivo data
showing FAK inhibition reduced CSC self-renewal, tumour
initiation, and overall tumour proliferation. A limitation of our
work is that we only evaluated the pTyr397 phosphorylation site,
which has been studied extensively in previous work6 and its
inhibition reduces CSC activity12,14. Although this phosphorylation
site within the central kinase domain plays a key role in FAKs’
contribution to cell motility6, there are other phosphorylation sites
and mechanisms of FAK activation. For example P53 is known to
bind to the FERM domain of FAK, and nuclear FAK has been
shown to regulate cell cycle progression via kinase independent
mechanisms in a SCC model6,24.
Previous studies into the effects of FAK inhibition in primary
patient tissue only include a small number of samples. Kolev et al
evaluated three patient derived samples12, whereas this study
uses 26 early invasive breast cancers, the largest evaluation of FAK
inhibition in patient samples. FAK inhibition reduced in vitro CSC
activity, measured by primary mammosphere formation, across all
molecular phenotypes in both cell lines and patient samples. A
reduction in primary mammosphere formation does not just
measure a reduction in self-renewal, it is also affected by changes
in apoptosis or proliferation25, leading to a reduced mammo-
sphere size. Therefore, we specifically evaluated self-renewal by
isolating single cells from primary mammospheres, treated with
FAK inhibitor or control, and re-plated these cells for secondary
mammospheres formation, with no further treatment. FAK
inhibition reduced self-renewal in primary patient samples in all
molecular subtypes, however two of the three ER− cell lines
(SKBr3 and SUM159) had a reduction in self-renewal after FAK
inhibition alone, which was not seen in either ER+ cell (MCF7 or
BT474). The different self-renewal response within patient samples
and cell lines may be attributed to their origin. Many of the cell
lines utilised were cultured from metastatic tissue such as pleural
aspirates and acquire genomic mutations as they are passaged,
and may not reflect the primary breast tumour. This may explain
the reduced sensitivity of cell lines to FAK inhibition compared to
primary patient derived tissue which is more representative of
early breast cancer. This was also demonstrated within our triple
negative breast cancer cell lines, where FAK inhibition reduced
self-renewal in the SUM159 cell line, which is established from a
breast tumour primary but not in the MDA-MB-231 cell line which
is established from a metastatic pleural aspirate. We propose that
FAK inhibition may prove to be more beneficial in the early breast
cancer setting than the metastatic setting where it is currently
being investigated26,27.
Additional data generated through SiRNA knockdown of FAK in
MDA-MB-231 cells also corroborate these suggestions, where a
greater reduction primary mammosphere formation is observed
and unlike with VS4718, self-renewal was also reduced. This is
likely explained by the fact protein knockdown generally produces
a bigger phenotypic effect and downregulation of associated
signalling than drug inhibition of its active site leading to SiRNA
but not VS4718 causing a reduction in the MDA-MB-231 cells.
Resistant breast tumour populations surviving in patients, as
residual disease, after receiving conventional treatments, endo-
crine therapy (letrozole), or chemotherapy (docetaxel), are
enriched for CSC tumour-initiating cell with mesenchymal
features28. Elimination of this resistant population is key to
improve long term survival in patients. In vitro investigations of
FAK inhibition in combination with Tamoxifen, Lapatinib, and
Paclitaxel, in ER+, Her2+, and triple negative breast cancers
respectively, demonstrated additional reductions in CSC activity
(primary mammosphere formation) with Lapatinib and Paclitaxel.
In particular VS4718 and Paclitaxel also reduced self-renewal in
triple negative primary breast cancer samples, showing the
potential for decreasing the number of residual therapy resistant
cells. Triple negative cell lines were shown to have elevated
pTyr397FAK expression in agreement with clinically derived data
indicating high FAK expression correlates with a triple negative
phenotype, p53 loss, lymphovascular invasion and a younger
age9,10. This data suggests that FAK inhibition is therefore a
potential target in this aggressive phenotype, where limited
treatment options are available. As such we further validated
these findings in two triple negative PDX models. PDX are the
most representative pre-clinical model producing faithful human
breast cancer pathologies, unlike cell line models, with epithelial
tumour heterogeneity and stromal tissue support. Thus, providing
a complex human tumour environment to evaluate effects of FAK
inhibition in combination with Paclitaxel on classic tumour
phenotypes, e.g., tumour size and proliferation. As well as using
the gold standard limiting dilution assay which allows tumour
initiation, the ultimate CSC characteristic, to be measured after
in vivo tumour treatments32, rather than the isolated CSC
properties within our in vitro CSC assays.
In two triple negative PDX models, we demonstrated combined
FAK inhibition and Paclitaxel treatment consistently reduced
tumour growth, proliferation and CSC activity. In vivo FAK
inhibition led to a reduction in mammosphere formation and
ALDH+ expression ex-vivo, which was not seen consistently after
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Paclitaxel treatment alone. Combined VS4718 and Paclitaxel
treatment also prevented the enrichment of ALDH+ expression
seen in RC37 PDX model after Paclitaxel monotherapy. Previous
combination studies using FAK inhibitor VS6063 and Paclitaxel has
been shown to overcome taxane resistance in an ovarian cancer
xenograft model, resulting in >90% reduction in tumour growth16.
However, we demonstrate that combined FAK inhibition and
Paclitaxel reduces tumour initiating capacity and subsequent
tumour re-growth in patient derived samples, (PDX) in line with
MDA-MB-231 and SUM159 xenograft studies12. Clinical use of a
FAK inhibitor in triple negative breast cancer is likely to be given in
combination with the current standard regime of chemotherapy,
given the poor outcome associated with this phenotype. We
believe this data demonstrates the potential additional benefits of
combining FAK inhibition with existing adjuvant therapies to
reduce resistant, residual disease which is enriched for CSCs.
Despite being the most representative pre-clinical model PDX
models are grown in severely immunodeficient mice, and thus the
role of FAK in regulating immune cells and the tumour micro-
environment (TME) could not be investigated in this work. FAK
inhibition in a pancreatic ductal carcinoma (PDAC) model
promotes CD8+ cytotoxic T cell recruitment and creates a less
fibrotic TME, rendering previously resistant PDAC cells sensitive to
Gemcitabine, T cell therapy and PD1 agonists29. The dense and
diffuse stroma, desmoplasia, which dominates the PDAC TME
plays a major role in driving treatment resistance in pancreatic
cancer and although less prominent in breast cancer it would be
interesting to correlate CD8+ and FAK expression in a breast
cancer cohort. Evidence of dual actions of a FAK inhibitor directly
on tumour CSCs and the TME would be an advantageous. Recent
studies in mouse mammary tumour models show when FAK
inhibitor is used in combination with endogenous or exogenous
signals that promote activation of T-cell co-stimulatory pathways,
e.g., CD80, 4-144BB, and Ox40, anti-tumour immune responses are
elevated and were capable of regression in some mouse models33.
Effects of FAK inhibition on metastasis could not be monitored
within our triple negative PDX models as spontaneous metastasis
were not present in the timeframe of tumours reaching their
maximum tumour burden. FAK deletion has been shown to
reduce lung metastasis in murine models12 and FAK inhibition
with VS4718 reduced metastasis in both 4T1, CAL-51, and MDA-
MB-231 xenograft models12,30. Therefore, investigation with an
appropriate metastatic PDX model would be warranted as CSCs
have been suggested to initiate breast cancer metastasis, as well
as FAK inhibition switching off classical focal adhesion driven cell
migration.
One key issue with targeting CSC in clinical trials is the lack of
validated biomarkers of CSC activity/response, which can be easily
measured in the lab using mammospheres, ALDH+ expression and
the gold standard limiting dilution model, measuring in vivo
tumour initiaiton32. We utilised ALDH1 and ITGα6, previously
shown to be two of the better markers in breast cancer patient
tissue23,31 however, these markers do not translate to PDX models.
Ideally a hetereogenous patient population would be utilised in
the form of a pre-surgical window or neoadjuvant trial to identify
and validate biomarkers in early breast cancer. This study should
include pre-treatment and post-treatment biopsies measuring
FAK, CSC markers, and other pathways shown to be involved in
CSC activity such as β-Catenin, alongside established laboratory
based functional assays of CSC activity to further evaluate the
response to FAK inhibition.
FAK inhibition alone reduces CSC activity across all molecular
phenotypes in patient samples. High FAK expression is associated
with poor clinical outcome and co-expression of high FAK and CSC
markers identify a high risk patient population, who may benefit
from FAK inhibition. Combined FAK and Paclitaxel treatment
consistently reduced CSC activity in cell lines, patient samples and
two triple negative PDX models. We believe this data provides
evidence that the effects of FAK inhibition in addition to
chemotherapy should be evaluated further in a neoadjuvant trial
in early breast cancer.
METHODS
Invasive ductal carcinoma cohort
A one recurrence (case) to two non-recurrence (control) cohort of 244
patients with invasive ductal carcinoma of non-specific type was created
using formalin fixed paraffin embedded cancer samples. We obtained
ethical approval from the Health Research Authority for this work under
project code REC14/SW/1170. These patients underwent surgical resection
between 2008 and 2011 at University Hospital South Manchester, with a
median follow-up time of 75 months. Electronic and paper records were
then used to record the patients clinical and histological details. The
clinicopathological characteristics of this cohort are described in Supple-
mentary Table 1. Tissue Micro Arrays were constructed with two epithelial
cores and one stromal core taken from each sample under the guidance of
Angela Cramer.
Immunohistochemical staining
All tissue was processed and cut in the same way by the histology
department at the Manchester Cancer Research Centre. Four millimeter
sections were mounted onto slides and baked at 60 °C overnight. Once
baked these slides were stained on the Leica Bond Max (up to a maximum
of 30 slides per run). During this automated process sections were
deparaffinised and dewaxed prior to heat-induced antigen retrieval. For
each antibody we ran a positive control and an isotype negative control to
ensure antibody specificity. Once stained, slides were dehydrated in a
series of alcohols (70, 90, and 100%) for 3 min each and then placed in
xylene for 5 min. Cover slips were added after being mounted with
permount solution.
FAK staining
Immunohistochemical staining for phospho FAK and total FAK was
performed using the Leica bond (Leica microsystems, Wetzlar, Germany).
Four micrometer paraffin embedded sections were cut 24 h prior to
staining and baked at 60 °C overnight. Staining for phosphorylated FAK
was undertaken using 44-624G Invitrogen antibody that binds to
phosphorylation site Y397. IHC had already been optimised by the breast
biology group at a concentration of 0.5 µg/ml, using epitope retrieval
solution 2 (pH9) for 20min, protocol F, casein blocking agent and the
refine polymer detection kit. pFAK was scored via visual microscopy of
TMA staining and high expression was defined as 2 or 3+ intensity in 90%
of cells.
Immunohistochemical staining for tFAK was undertaken on the Leica
bond using anti-FAK clone 4.47, Merck Millipore at a 1 in 250 dilution.
Epitope retrieval solution 2 (pH 9) was used for 20min using standard
protocol F and the refine polymer detection kit. tFAK was scored via visual
microscopy of TMA staining and high expression was defined as 3+
intensity in 20% of cells.
ITGa6 staining
Immunohistochemical staining for ITGα6 was undertaken on the Leica
bond using Atlas antibody HPA012696. We used a 1 in 250 dilution,
epitope retrieval solution 2 (pH 9) for 20minutes, standard protocol F and
the refine polymer detection kit. ITGα6 staining was scored via visual
microscopy of TMA staining and high expression defined using Friedrich’s
et al criteria of grade III and IV expression in greater than 5% of
epithelial cells.
pFAK, tFAK, and ITGα6 were scored using visual microscopy by two
independent scorers, Simon Timbrell and Hosam Aglan. These scorers
received training from Angela Cramer who counter scored 10% of samples
and checked any discrepancies between the two scorers. Tissue samples
were scored based on intensity and the percentage of epithelium staining
positive with 500 cells per core being counted.
Dual ALDH1/CK18 immunofluorescence staining
Given the non-specific nature of the IHC ALDH1 staining, we utilised an
immunofluorescent protocol with co-staining using epithelial marker
Cytokeratin 18 staining. We used the BD bioscience ALDH1 antibody
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611195 at a 1 in 250 dilution. For the CK18 staining we used the Ab668
antibody at a 1 in 2000 dilution.
Slides were prepared as described above and then loaded on the
Ventana DISCOVERY Ultra automated system. Following deparaffinisation
slides were incubated for 8 min with cell conditioner 2 solution
(pH6 solution). DISCOVERY Inhibitor was added for 8 min to inactivate
endogenous tissue enzymes. Ab668 (ALDH1 antibody) was manually
applied at a 1 in 250 dilution and incubated for 60min. Slides were then
incubated with DISCOVERY Omni Map anti-Ms HRP (horseradish
peroxidase-linked anti-mouse IgG) for 16min. The red fluorophore
Opal670 (1 in 100) was then manually applied to slides to visualise
ALDH1 staining and incubated for 12min. The above sequence was
repeated for the CK18 antibody (1 in 2000). The green Opal540 (1 in 100)
fluorophore was used to visualise CK18 staining. Slides were washed twice
in EZ Prep solution for 5 min and then in water once, for 5 minutes. Slides
were mounted with Prolong Gold which contains a DAPI nuclear stain.
Liver tissue was used as a positive control for ALDH1 staining. Dual staining
was scored via automated detection using the HALO analysis software.
With high staining being defined as >5% positivity within epithelial cells.
Ki67 staining
Immunohistochemical staining for Ki67 was undertaken on the Leica bond
using DAKO antibody (M7240) at a 1 in 250 dilution with epitope retrieval
solution 2 (pH 9) for 20min, standard protocol F and the refine polymer
detection kit. Once stained these sections were scanned using the Leica
scanner and the presence of DAB staining evaluated using the HALO
analysis software.
Cell lines
MCF10a and DCIS.com lines were purchased from Asterand. MCF7, BT474,
SKBr3, MDA-MB231, and SUM159 lines were purchased from ATCC. Human
breast carcinoma cell lines were grown in monolayer in their correspond-
ing media and maintained in a humidified incubator at 37 °C at an
atmospheric pressure of 5% (v/v) carbon dioxide/air. Cells were passaged
via washing with PBS, addition of trypsin for 2–4min and then spun down
into a cell pellet. The supernatant was discarded, and the cells re-
suspended in media and placed in a new flask.
Mammosphere culture
Prior to the isolation of cells, 6-well plates were pre-coated with 1ml of
polyhema and baked for 48 h at 60°C. Single cells were isolated from cell
lines, primary or in vivo tissue. In order to ensure single cell suspension,
further disaggregation was undertaking by passing the cell solution
through a 25G needle a maximum of three times at which point the cell
concentration would be re-counted.
These single cells were seeded in mammosphere media at densities of
500 cells per cm2 and incubated at an atmospheric pressure of 5% (v/v)
carbon dioxide/air. Cell lines were incubated for 5 days whilst human
samples and PDX tumours were incubated for 7 days prior to counting.
After incubation mammospheres were counted based on a size greater
than 50mM at 40 times magnification. The mammosphere forming
efficiency was calculated as shown below:
Mammosphere forming efficiency MFEð Þ ¼ Number of mammospheres> 50μMNumber of single cells seeded ´ 100
In order to evaluate CSC self-renewal, these primary mammospheres
were then passaged without further treatment into non-adherent
culture conditions. Primary mammospheres were counted and then
extracted from the 6-well plates into a universal container and
centrifuged at 200×g for 2 min. Mammospheres were then dissociated
into single cells via enzymatic digestion with trypsin and mechanically
disaggregated by passing through a 25G needle for ten times. Single
cells were re-seeded in mammosphere culture conditions described
above with no further treatment. After 5 days of incubation (7 days for
primary cells) the number of secondary mammospheres formed were
counted and the following calculation used to evaluate mammosphere
self-renewal:




Many common materials and methods were as described Williams
et al.14 and the mammosphere protocol described in Shaw et al.21. IHC
antibodies are as follows; FAK, anti-FAK clone 4.47, Millipore, 1:250 dilution;
PTyr397 FAK, 44-624 S, Invitrogen, 0.5 µg/ml; ITGα6, HPA012696, Atlas,
1:250; Ki67, M7240, DAKO antibody,1:250. All blots derive from the same
experiment and were processed in parallel.
Immunoblot analysis
Lysates were collected as outlined in this section unless otherwise stated.
Cells were grown in monolayer in 10 cm2 petri dishes for 24 h. Cells were
then washed twice with ice cold PBS and 250 µl of lysis buffer added to the
dishes. After 2 min cells were removed via scraping. The detachment of
cells was confirmed on microscopy. The cell lysate was the placed on a
rotator at 4 °C for 1 h. After which the cell suspension was centrifuged for
10min at 200 × g and the supernatant collected.
The BIORAD assay solution was then used to determine the protein
concentration. Reference protein concentrations were made as per the
manufacturer’s guidelines using a BCA assay included in the kit. Two
hundred microliter of protein analysis solution was added to 10 µl of 1 in
10 diluted lysate sample. Protein concentrations were then calculated
using the 552 nm laser on the VersaMax ELISA microplate reader. The
amount of lysate required to load 40 µg of protein per lane was then
calculated. This volume of lysate was then mixed with 4× Laemmli sample
buffer. Proteins were then denatured by heating the lysates to 90 °C for
10min.
Forty microgram of denatured lysate was loaded to each well of a Mini-
PROTEAN gel with a 10 µl of precision plus kaleidoscope prestained protein
standard used as a reference ladder. Gels were run at 120–200 V until the
37 kDa approached the bottom of the gel usually taking 1 h at 150 V. A wet
transfer was undertaken using the Hybond-C extra nitrocellulose
membrane at 30 V overnight. After transfer Ponceau S solution was used
to assess the validity of protein transfer.
Membranes were blocked with their corresponding blocking agents
shown in Table 2.1.7 for 1 h and then washed three times. Each was
undertaken with TBS-Tween for 10min. Primary antibodies were made up
in the same solution that the membrane was blocked with and incubated
at room temperature for 1 h or overnight at 4 °C. Membranes were washed,
re-blocked and exposed to the appropriate secondary HRP prior to ECL
exposure. Membranes were developed using the BIORAD ChemiDoc touch
system and relative protein densities analysed using Image Lab software.
Aldefluor assays
The Aldefluor assay kit from STEMCELL Technologies was utilised to
identify ALDH+ expression. 1,000,000 cells were suspended in 1ml of
aldefluor buffer to which 5 µl of BAAA was added and incubated for 40min
at 37 °C. Each sample had a DEAB control with a 0.1% gate utilised during
the quantitative analysis. During the flow sorting analysis 7AAD
(Bioscience) was utilised as a live-dead stain. H2KD antibodies (Biolegend)
conjugated with pacific blue fluorophore were used to exclude mouse
stromal cells during PDX experiments.
siRNA transfection
A set of four individual pre-designed siRNA’s targeting PTK2 (the gene
encoding for FAK) were purchased from Dharmacon alongside positive
control GAPDH and scrambled negative control. A range of concentrations
of siRNA (25–50 nM) were trialled, at a range of different time points
(48–72 h), on a range of different cell densities 10,000, 50,000, and 100,000
cells per 10 cm2 plate for MDA-MB 231 and SUM159 cells. siRNA constructs
were used as single agents and in combination with the effect on tFAK
expression measured by western blot analysis. Cells were seeded 24–48 h
prior to transfection and washed prior to exposure to transfection media.
The siRNA transfection media was prepared by adding 10 µl of siRNA and
190 µl of serum-free media to one tube and 10 µl of transfection reagent to
190 µl of serum free media in another tube. These separate tubes were
incubated at room temperature for 5 min prior to mixing. Once mixed this
solution was incubated for a further 20min at room temperature prior to
the addition of a further 1600 µl of DMEM media containing FCS and L-
glutamine. This created a 50 nM solution in 2ml of media, which was
added to a 10 cm2 culture plate. Cells were incubated with this media for
48–96 h. After a maximum of 96 h cells were then collected for western
blot analysis or isolated as single cells for mammosphere culture and
Aldefluor expression analysis.
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Isolation of epithelial cells from human tumour samples
Primary patient tumours were collected by the Manchester Biobank on
invasive ductal tumours >1.5 cm. Informed consent was taken by the
Manchester Biobank team with a project ethics code of 05/Q1403/159. The
MCRC Biobank is licensed by the Human Tissue Authority (licence
number:30004) and has been ethically approved as research tissue bank
by the South Manchester Research Ethics Committee (Ref:18/Nw/0092).
Excised surgical specimens were placed in RPMI media with FCS, L-
glutamine, penicillin and streptomycin, and a piece of tumour removed
under pathologist review. Tumours were cut into chunks and enzymatically
digested using the Miltenyi tumour dissociation kit and protocol.
Patient derived xenograft studies
All in vivo studies were carried out in accordance with UK home office
(Scientific Procedures) Act 1986 under project licence PCFEC0D4 and with
approval of the CRUK Manchester Institute Animal Welfare and Ethics
Review Board. We selected two triple negative PDX models based on RNA
expression of FAK (PTK2B), ALDH1A1 and ITGα6 expression, Supplementary
Fig. 5b. FAK and pTyr397FAK IHC expression was confirmed as moderate/
high within the RC37 and RC193 model selected (Supplementary Fig. 5c,
d). Tumours were implanted fresh as 2 × 2mm chunks into bilateral flanks
of NOD scid gamma (NSG) female mice aged 6–8 weeks. Mice were
measured twice weekly and all treatment was started at the same time
point when combined tumour volume was 250–300mm3 per mouse, with
treatment lasting up to 4 weeks as shown in the overview in
Supplementary Fig. 5a. Control mice received vehicle only. VS4718 was
given via oral gavage at 50mg/kg B.D on weekdays only. Paclitaxel was
administered weekly via intraperitoneal injection 7.5 mg/kg. Tumour
volumes were recorded twice weekly via calliper measurement until the
combined tumour burden exceeded 800mm3 at which point it was
measured daily. All mice were checked for visible signs of toxicity and
weighed daily; throughout the treatment no toxicity was seen. Tumours
were harvested when total tumour burden per mouse reached 1250mm3
and placed in media prior to processing.
In order to evaluate the effects of FAK inhibition and paclitaxel
treatment on the tumour initiating capacity of treated mouse tumours, we
undertook a limiting dilution assay. During this assay single cells from
treated PDX tumours were injected subcutaneously into the flanks of 6–8-
week-old NSG mice at a range of cell dilutions. Cells were defrosted, spun
down and viable cells counted with trypan blue prior to injection. Each
mouse received an injection made up of 200ml per flank containing
100ml of media and 100ml of matrigel. This matrigel media mix contained
a range of cell concentrations and was injected via 25G needle.
Statistical analysis
Cancer disease and recurrence free survival were calculated using cox-
regression (Hazard Ratio and 95% confidence intervals). In vitro mammo-
sphere data are represented as mean ± SEM taken over ≥3 independent
experiments, ≥3 technical replicates per experiment, unless otherwise
stated. Statistical significance was measured using analysis of variance
(ANOVA) test with post-hoc Tukeys or Dunnett’s multiple comparison, or
student t-test using graph pad prism. A p value of less than 0.05 was
considered significant and all statistical tests were two-sided. All statistics
were carried out under the guidance of statistician P Foden.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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